Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacokinetics
4 evidence topics · 5 sources
Absorption, half-life, accumulation, and steady state: healthy volunteers and congenital hyperinsulinism
“In healthy volunteers and individuals with congenital HI, ersodetug displays dose-proportional pharmacokinetics after intravenous administration, with peak serum concentrations observed within approximately 2 hours, an effective half-life of about 15 days (terminal elimination half-life 15-28 days), modest accumulation with repeat dosing, and concentrations that are predicted to approach or exceed 90% of steady-state within roughly 4-8 weeks depending on dosing frequency, with steady-state generally achieved by about 12 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote